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ABSTRACT 
The third leading cause of cancer deaths in the U.S. is colon cancer. The major 
disadvantage of cancer chemotherapy is its non-selective toxicity to healthy cells at the 
therapeutic doses. A possible target selective for cancer cells is their dependence on 
glycolysis for cellular energy. 2-deoxyglucose (2-DG) is a glycolytic inhibitor that has been 
shown to be safe in both animals and humans.  The molecular mechanisms for the anti-
cancer effect of 2-DG cannot be explained solely by its glycolytic inhibition. In this 
manuscript we studied the effect of 2-DG on colon cancer cells and its possible molecular 
mechanism. Colon cancer cells are more susceptible to 2-DG treatment than other 
cancerous and non-cancerous cell lines tested. The colon cancer cells tested are SW620, 
SW480 and GC3/C1. In cell cycle analysis studied using propidium iodide staining of DNA 
followed by flow-cytometry, 2-DG induced cell cycle arrest at G0/G1 phase in SW 620 
cells. 2-DG also modified the expression of various cell cycle proteins such as p21, p53, 
and cyclins as measured through Western Blotting. In addition to cell cycle arrest, 2-DG 
also induced apoptosis through activation of Caspase 3. Complementing 5-Fluorouracil (5-
FU) treatment of colon cancer cells with 2-DG significantly enhanced the efficiency of 5-
FU treatment up to 3.5 fold.  This study showed a new molecular mechanisms for 2-DG 
that could be used to design novel combination therapies with other known 
chemotherapeutic agents for colon cancer. The addition of a well-tolerated molecule like 2-
DG increases the efficiency of 5-FU, thus reducing the patient’s cumulative exposure to 5-
FU. This may lead to fewer dose dependent side effects and better patient outcomes. 
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INTRODUCTION 
Colorectal cancer is the third deadliest form of cancer in the United States.  It is estimated 
that 102,480 people will be diagnosed with colon cancer and it will be responsible for 
50,830 deaths in 2013 alone (Siegel et al., 2013). The most widely used chemotherapeutic 
agent to treat colorectal cancer, as a single agent and in combination regimens, is 5-
Fluorouracil (5-FU) (Cersosimo, 2013).  The greatest challenge with chemotherapeutic 
agents, like 5-FU, is that they cause severe systemic toxicity at their therapeutic doses.  
This brings up a need to develop and identify drugs that are effective as well as exhibit a 
safe drug profile.  A new class of drugs, glycolytic inhibitors, is selective for cancer cells 
based on the Warburg hypothesis.    
Otto Warburg observed in the early 1920’s that cancer cells differ from normal cells in their 
primary source for energy. All cells need energy in the form of ATP for their survival, but 
cancer cells need more energy than healthy cells because of their uncontrollable growth. 
Usually, cellular energy (ATP) comes from glycolysis and the Tricarboxylic Acid cycle-
coupled oxidative phosphorylation of glucose. In the presence of oxygen, healthy cells 
depend on oxidative phosphorylation for their main source of energy. Warburg observed 
that cancer cells typically produce the majority of their ATP by glycolysis, even in the 
presence of oxygen. Cancer cells are characterized by their higher rate of lactate release and 
increased glucose consumption rate.  The dependency of cancer cells on glycolysis as their 
primary source of energy makes this enzymatic pathway a key target for drug therapies. 
Accordingly, various small molecule inhibitors of the glycolytic pathway have been used 
effectively in the past to halt the progression of cancer both in-vitro and in-vivo (Gatenby & 
Gillies, 2007; Knight et al., 1996). 
2-Deoxyglucose (2-DG) is a well-characterized small molecular inhibitor of glycolysis both 
in animals and humans (Maschek et al., 2004; Vander Heiden, et al., 2009). It is safe and 
well tolerated in mice and rats (Kang & Hwang, 2006). Studies have also shown that doses 
of 2-DG as high as 200 mg/kg are well tolerated in people (Scatena et al., 2008). 2-DG is a 
glucose molecule in which hydrogen takes the place of the hydroxyl group on the second 
carbon. Similar to glucose, 2-DG gets transported into the cell by glucose transporters.  It 
then can be phosphorylated by hexokinase to form 2-DG-P. However, unlike glucose-6-
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phosphate, 2-DG-P cannot be metabolized further by phosphohexose isomerase and cannot 
be easily transported out of the cell. The accumulation of 2-DG-P in the cell causes 
feedback inhibition of hexokinase. This block of glycolysis is especially harmful to tumor 
cells which rely heavily on glycolysis for their ATP generation (Scatena et al., 2008).  
However, recent research has shown that there may be other mechanisms involved with 2-
DG anti-cancer effects in addition to its glycolytic inhibition. Firstly, the decline in ATP 
levels following 2-DG treatment in eukaryotes is moderate at best (Stein et al., 2010). 
Secondly, tumor cells react differently to 2-DG than its fluorescent analogue 2-
Fluorodeoxy-D-Glucose (FDG). Although FDG is also a stronger inhibitor of glycolysis, it 
is non-toxic to cells that were responsive to 2-DG (Qutub & Hunt, 2005).  Taken together, 
these findings suggest the existence of additional cellular effects or targets for 2-DG. 
In this manuscript, the additional cellular effects of 2-DG, apart from inhibiting glycolysis, 
in colon cancer cell lines were evaluated. The results showed that 2-DG arrests the cell 
cycle at G0/G1 by modulating cell cycle proteins such as p21, p53 and cyclins. This cell 
cycle arrest subsequently results in cell death by apoptosis. More cancer cells were killed 
when 5-FU treatment was complemented with a safer molecule like 2-DG. 
METHODS 
Cell culture and drug treatment 
Three human malignant colorectal cancer cell lines (Gc3/C1, SW480 and SW620), two 
human breast cancer cell lines (MDA-MB-231 and MCF7), a human ovarian cancer cell 
line (Ovcar3), a human melanoma cell line (B16F10) and a human kidney epithelial cell 
line (HEK 293T) were used in this study. The cells were grown in RPMI 1640 (Ovcar3 and 
Gc3/C1), DMEM (MCF 7, MDA-MB-231, B16F10 and HEK293) or Leibovitz’s L-15 
medium (SW620 and SW480) supplemented with 10% fetal calf serum (FCS), penicillin 
(100U/ml), and streptomycin (100µg/ml) in a humidified incubator (37°C, 5% CO2). A 1 M 
stock solution of 2-DG (Sigma, St. Louis, Mo.) was prepared in 50 mM phosphate buffered 
saline (PBS), stored at -20°C and diluted in the complete media to obtain the desired 
concentrations.  
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Cytotoxicity assays and the determination of IC50 of 2-DG and 5-FU 
The dose of 2-DG and 5-FU required to kill 50% of cells (IC50) in various cell lines was 
determined by MTT (3,4,5-dimethiazol-2,5-diphenyl-tetrazolium bromide, Sigma) assay. 
Ten thousand cells were seeded per well of a 96 well plate and allowed to adhere for 24 
hours. After incubating the cells for 72 hrs with various concentrations of 2-DG (0 – 25 
mM) and 5-FU (0-50 μM), the viability of the cells was assessed using MTT assay. The 
IC50 was calculated using SigmaPlot® software by plotting the cell viability against the 
concentration of 2-DG. All the experiments were performed in replicates of three with three 
repetitions.  
Efficiency of 5-FU in combination with 2-DG in colorectal cancer 
cell lines 
The cells were treated with a range of 5-FU (0-50 μM) and a fixed amount of 2-DG (0.25 
mM for SW480 and SW620 and 0.025 mM for GC3-C1). The effectiveness of the 
combination therapy of 5-FU with 2-DG was determined by comparing the IC50 of 5-FU 
alone or in combination with 2-DG. All the experiments were performed in replicates of 
three with three repetitions. Statistics to test for significant difference in variance was 
performed using the Student’s t-test at P<0.05. 
Protein isolation and Western blotting 
Cells were treated with the various concentrations of 2-DG in a 6-well plate and incubated 
for different time periods following which, total cell protein was extracted using 0.25 ml 
cold fresh lysis buffer (1% Triton X-100, 150 mM NaCl, 0.5 mM MgCl2, 0.2 M EGTA and 
50 mM Tris-HCl (pH 7.5) with aprotinin (2 µg/ml), DTT (2 mM), and 
phenylmethylsulfonyl fluoride (PMSF, 1 mM)). Proteins from the cell lysates were 
separated on a 10-15% polyacrylamide gel under reducing conditions (reducing, SDS-
PAGE). Proteins were then transferred onto nitrocellulose membrane, and the blot was 
blocked with 5% non-fat milk. The protein levels were detected by immune-detection with 
specific antibodies. Anti-p21, anti-CDK4, anti-CDK2, anti-Caspase 3 (SantaCruz 
biotechnologies, CA), and anti-β tubulin antibodies (Developmental Hybridoma Bank, IA) 
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were used at a concentration of 1:1000 dilution. Anti-cyclin D1, A and E polyclonal 
antibodies (SantaCruz biotechnologies, CA) were used at a concentration of 1:250 dilution. 
Appropriate HRP-conjugated secondary antibodies (SantaCruz biotechnologies, CA) were 
incubated at room temperature at a dilution of 1:5000. The specific protein complexes were 
identified using a chemiluminescence detection kit (Amersham, CA).  
Cell cycle analysis   
The cell cycle analysis was performed following the method described in the literature 
(Liu, Li, & Raisch, 2010) . In brief, SW620 cells were switched to media without serum for 
a period of 24 hours, to render them quiescent and synchronize their cell cycle phases. 
Following this, the cells were treated with various concentrations of 2-DG for 18 hours and 
harvested by trypsinization. The harvested cells were washed twice with PBS and fixed in 
70% ethanol at 4°C. The nuclear DNA was stained using propidium iodide (50 µg/ml) in 
the presence of DNase free RNase (2U/ml). The cells were sorted depending on the DNA 
content using a fluorescence activated cell sorter (FACS) (BectonDickinson, San Jose, 
CA). The proportion of cells in each phase of the cell cycle was determined using CellFIT 
software (BectonDickinson, San Jose, CA). 
RESULTS 
1. Colorectal cancer cells are more susceptible to 2-DG treatment 
The cytotoxic effect of 2-DG on various cancer and non-cancer cell lines was tested using 
the MTT assay. The types of cell lines tested were non-cancer kidney epithelial cell line 
(293T), colorectal cancer cell lines (SW620, SW480 and GC3/Cl), breast cancer cell lines 
(MDA-MB-231 and MCF7), ovarian cancer cell line (Ovcar 3), and melanoma cell line 
(B16F10).    The IC50 of 2-DG on various cell lines is represented in Figure 1. Out of eight 
cell lines tested, 2-DG exerted the least cytotoxic effect on the non-cancer cell line (HEK 
293, IC50: 6.452 mM), which further supports its enhanced selectivity towards cancer cells. 
The metastatic aggressive breast cancer cell line (MDA-MB-231, IC50= 1.874 mM) was 
more susceptible to 2-DG treatment than non-metastatic cancer cells (MCF7a, IC50= 
5.891mM). The IC50 values of the three colorectal cancer cell lines were lower than that of 
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other cancer cell lines tested. Since colorectal cancer cells were more susceptible to 2-DG 
treatment than other cancer cells tested, and to maximize the subsequent output, we chose 
to use colorectal cancer cells (SW620) for further analysis of 2-DG activity in the Western 
blotting and cell cycle analysis. 
 
Figure 1. The IC50 values of 2-DG in various cancer cell lines after 72 hour treatment 
at various concentrations (mM) of 2-DG. The colorectal cancer cell lines (represented 
in red) SW620, SW480 and GC3/Cl exhibit the highest sensitivity to 2-DG treatment. 
The data represent the average of triplicates.  
2. 2-DG inhibits cell cycle progression in colorectal cancer cell lines 
The reduced viability of cancer cells after 2-DG treatment could be interpreted as a result of 
inhibiting cell cycle progression or inducing cell death or both. Therefore, the role of 2-DG 
in modulating the cell cycle progression was evaluated in SW620 cell line using flow 
cytometric analysis as described in the methods. Treatment of SW620 cells with 2-DG for 
18 hours caused cell cycle arrest at the G0/G1 checkpoint (Figure 2). The percent of cells in 
G0/G1 significantly increased from 63.49 % to 80.15 % (P<0.05; student T-test) after 2-DG 
treatment. Simultaneously the number of cells in S phase decreased from 19.11 % to 7.13 
%. 
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Figure 2. Cell cycle analysis of SW620 cells following 18 hour treatment with 20mM 2-
DG using flow cytometry. Control cells A, and treated cells B, were fixed and stained 
with propidium iodide and analyzed for DNA content using flow cytometery. The data 
represents mean percent of cells in a particular cell cycle phase ± standard deviation 
(n=3). 
3. 2-DG increases the expression of p21 and p53 proteins 
Cyclin Dependent Kinase (CDK)-inhibitory proteins, designated as CKIs (18) play a 
critical role in modulating the events of cell cycle. p21 is one of the key CKIs exerting a 
regulatory role in cell cycle progression. The expression of p21 can be p53 mediated or p53 
independent. The direct effect of 2-DG on the expression of these proteins in SW620 cells 
was analyzed by Western Blot analysis (Figure 3 A). Treatment with 2-DG increased the 
expression of p21 as well as p53 in SW620 cell lines. This increase was dependent on the 
dose of 2-DG (Figure 3 A). To check the kinetics of p21 and p53 expression, SW620 cells 
were treated with 5 mM 2-DG for various time periods and the amount of p21 and p53 
proteins in the cell lysate was analyzed by western blot analysis. 2-DG dependent increased 
expression of p21 was transient with the maximum expression occurring after 18 hours of 
treatment (Figure 3 B). The protein levels of p53 reached a plateau at 18 hrs following 2-
DG treatment. 
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Figure 3 A. Effect of different doses of 2-DG treatment on anti-apoptotic p53 and p21 
protein expression in SW620 cells. The cells were treated for 48 hours.  
Figure 3 B. Transient expression of p21 in SW620 cells. Cells were treated with 5mM 
2-DG for indicated time points. For both western blots, whole cell protein was 
extracted and ran on 12% acrylamide gel. The beta tubulin concentration was 
constant, showing that equal amounts of cell protein was loaded in each well. Beta-
tubilin was used as a loading control in the blots.  
4. 2-DG alters the expression of various cell cycle associated proteins 
Expression levels of various proteins involved in cell cycle are critical for proper progression 
of cell cycle (Madhok et al., 2010). The 2-DG treatment decreased the expression of various 
proteins associated with cell cycle progression (Figure 4). 2-DG treatment caused a down 
regulation of cyclin A, cyclin D and CDK4, whereas the levels of CDK2 and cyclin E 
















Figure 4. Relative expression of various cell cycle proteins. SW620 cells were treated 
with the indicated doses of 2-DG for 18 hours. The expression levels of various cell 
cycle associated proteins were checked by western blot analysis. The figure is a 
representative image of three separate experiments.  
5. 2-DG causes cell death through apoptosis or cell death 
Cell cycle arrest at G1/G0 phase and the transient over expression of p21 protein may direct 
the cells towards apoptosis (Wu et al., 2002).  To check whether the treatment of 2-DG 
causes the induction of apoptosis, SW620 cells were treated with various doses of 2-DG 
and apoptosis was analyzed by investigating an apoptotic marker protein called caspase 3. 
Caspase 3 exists in all cells, but this protein is cleaved during apoptosis and the cleaved 
caspase is active and acts as an effector protease during apoptosis. (Wolf et al., 1999).  As 
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Figure 5. Expression of cleaved caspase 3 following the treatment with 2-DG in SW 
620 cells.  The control well was not treated with 2-DG. This is representative of three 
separate experiments. 
6. The combination of 2-DG with 5-FU reduces the IC50 of 5-FU 
Once the effect of 2-DG on cell cycle and apoptosis was established, the complementary 
effect of 2-DG on the efficiency of 5-FU was investigated.  The IC50 of 5-FU was reduced 
by the addition of 0.25 mM of 2-DG in SW480 and SW620 while 0.025 mM of 2-DG was 
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Cell line IC50  Fold enhancement 
provided by co-
application of 5-
FU and 2-DG 
5-FU alone (μM) 5-FU (μM) + 2-
DG (0.25 mM) 
SW620 9.25±0.32* 5.23±0.18* 1.77 
SW480 15.28±1.02* 5.17±0.54* 2.96 
GC3/Cl# 13.27±1.09* 3.75±0.38* 3.54 
#The concentration of 2-DG used in GC3/C1 was 0.025 mM 
*Shows significant difference in variance by Student’s  t-test at P<0.05 
 
Table 1. The IC50 values of 5-FU alone and in combination therapy with 2-DG in 
various cancer cell lines after 72 hour treatment at various concentrations of 5-FU. In 
all cases, 2-DG enhanced sensitivity compared to 5-FU alone. The data represents the 
average of triplicates. 
DISCUSSION 
Current first line treatment of colorectal cancer, 5-FU as a monotherapy or in combination 
therapy, has the major drawback of extensive tissue toxicity.  The major side effect of 5-FU 
is myelosuppression, which can lead to many other health complications  (DiPiro et al., 
2011).  For this reason, developing anticancer agents with less toxicity to normal tissues 
would be desirable.  An example of a drug with such an ideal safety profile is 2-DG.  It is 
known to block glycolysis by inhibiting the key glycolytic enzyme hexokinase (Scatena et 
al., 2008).  However, the full array of effects of 2-DG in cancer cells cannot be completely 
explained by its inhibitory effects on the glycolytic pathway (Qutub & Hunt, 2005; Stein et 
al., 2010). In this manuscript, we have identified a plausible new mechanism of 2-DG on 
colorectal cancer cells.  Colorectal cancer cells were more susceptible to cytotoxic effects 
of 2-DG when compared to other cancer or non-cancer cell lines tested. The IC50 values of 
2-DG in colorectal cancer cells was almost four-fold lower than in non-cancerous HEK293 
cells. This finding is consistent with the fact that 2-DG is a useful therapeutic agent and 
exerts minimum toxic effects in-vivo on non-cancerous cells (Kang & Hwang, 2006). The 
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increased potency of 2-DG in colorectal cancer makes it an attractive candidate for such 
types of cancer where local high concentrations of the drug can be achieved using novel 
formulation strategies such as colon targeted drug delivery (Philip & Philip, 2010).   
It was observed that 2-DG shifts the SW620 cells G0/G1 phase and sharply decreases the 
numbers in the S phase during the cell cycle analysis.  The cell cycle inhibition may be 
attributed to the transient expression of p21, a Cyclin Dependent Kinase Inhibitor (CKI). 
Moreover, the transient increase in expression of p21 was independent of p53 levels and this 
observation might suggest the molecular effect of 2-DG on p21 levels, irrespective of p53 
status. Furthermore, the expression levels of various cell cycle associated proteins such as 
cyclin A, cyclin D1 and CDK4 were also reduced.  Such a reduced expression of CDK4 and 
other cell cycle-associated proteins may be responsible, in part, for the G1/G0 cell cycle 
arrest observed after 2-DG treatment (Figure 2). During the treatment of SW620 with 2-DG, 
increased amounts of cleaved caspase were seen in the treated versus the untreated cells. An 
expression of cleaved caspase 3 such as this indicates that the cells are undergoing apoptosis.  
The implications for these findings would be the ability to identify potential new synergistic 
combination therapies of 2-DG with other chemotherapeutic agents that have similar 
apoptosis inducing mechanism. 2-DG has had very limited success as a single agent in 
treating cancer (Kurtoglu et al., 2007).  What is promising though are the studies in which 2-
DG is used in combination therapy.  In mice that bear human osteosarcoma or non-small cell 
lung cancers, 2-DG has been shown to drastically increase the anticancer efficacy of 
adriamycin and paclitaxel (Maschek et al., 2004).  As far as potential for combination therapy 
in colon cancer, a recent paper has found that the drug lupulone induces the expression of 
p53 in both SW480 and SW620 cells through activation TRAIL death receptor signaling 
pathways (Lamy et al., 2010).  Since 2-DG and lupulone both induce p53 expression, this 
brings up the potential of a synergistic combination therapy.  By identifying other drugs that 
have similar mechanisms in colorectal cancer, more combination therapies can be tested.  
2-DG is a very safe molecule for cancer treatment, however, it is very challenging to achieve 
the therapeutic concentration of 2-DG in a clinical setting (Figure 1: IC50 in SW620 is 
~1.436 mM). Therefore, we have proposed to use 2-DG as an adjunct therapy at 
concentrations from 0.025 mM to 0.25 mM with existing chemotherapy to enhance the 
efficiency of chemotherapy. The complementary therapy of 5-FU with 2-DG was also 
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established by analyzing the increased efficiency of 5-FU killing of the colorectal cancer cell 
lines in the presence or absence of 2-DG.  The IC50s of FU decreased 1.77 to 3.54 fold, 
depending on the cell line used, when 0.025-0.25 mM 2-DG was co-administered. 2-DG is a 
safe drug in large concentrations in both humans and animals (Scatena et al., 2008).  By using 
small concentrations of 2-DG, and the range used was monumentally smaller than the IC50 
of our normal cell (Figure 1: IC50 in HEK 293T is ~6.251 mM), a drop in the amount of 5-
FU needed to kill half of the cancer cells sharply decreased. The implications for this finding 
would be that doses of 5-FU required to treat colon cancer could be reduced when 2-DG is 
given with 5-FU. This will potentially reduce side effects of 5-FU as the side effects depend 
on the dose of 5-FU. This could lead to better health outcomes and an improved quality of 
life in colon cancer patients. 
Future studies are needed to establish independence of the plausible new mechanism of 2-
DG from glycolytic inhibition in these cell lines.  In vivo experiments will also be 
necessary to see if these effects of 2-DG hold true in an animal model.  In vivo experiments 
will allow us to design a dosage form system that could release the combination therapy of 
5-FU with 2-DG once it reaches the colon.  This would allow the medication to be released 
and be in the highest concentration in the colon. A successful development in this dosage 
form would further reduce chemotherapy exposure to other parts of the body not 
necessitating chemotherapy. 
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